Harden Announces Strategic Sale of the 3 rd Phase of Méga Centre Notre-Dame, Accelerating Laval Redevelopment and Community Growth
As part of a shared vision to unlock the full potential of this highly visible and accessible site along Highway 13, the Harden-RioCan partnership is reinvesting in the retail component of the property following the sale. The portion sold to Rosefellow was a less productive area of the site. This strategic disposition enables targeted reinvestment into the retail core of Méga Centre Notre-Dame, accelerating its transformation into a productive, dynamic destination for residents, workers, and visitors alike.
'We are proud to continue our role in strengthening Laval's retail and commercial environment,' said Tyler Harden, Co-Chief Executive Officer, Harden. 'This sale supports a broader redevelopment vision that brings new energy and economic growth to the area. With new retailers like Sephora already open, Krispy Kreme on the way, and major expansions by iconic brands such as Winners/HomeSense, Gap, Banana Republic, La Vie En Rose, Dollarama and Poulet Rouge, Méga Centre Notre-Dame is entering a new chapter that reflects our dedication to creating lasting value for residents and businesses alike.'
This transformation includes the expansion of Winners/HomeSense into one of the largest stores of its kind in Quebec, with a footprint of approximately 70,000 square feet, and a significant expansion by Dollarama. These enhancements, coupled with the arrival of high-profile brands like Sephora, reinforce the centre's appeal and solidify its role as a commercial anchor in Laval.
'This transaction highlights the strength of our retail portfolio and our ability to strategically unlock value from well-located assets,' said Jonathan Gitlin, President and CEO, RioCan Real Estate Investment Trust. 'By monetizing a less productive portion of the site at an 80% premium to IFRS value and reinvesting in its high-performing core, we have strengthened the long-term viability of Méga Centre Notre-Dame and delivered meaningful value for our unitholders."
Rosefellow's planned $200 million redevelopment will introduce three state-of-the-art industrial buildings, meeting the growing regional demand for high-performance logistics and light industrial space. This development will complement the centre's retail operations, creating a mixed-use hub that draws value from both sectors while serving the evolving needs of the community.
A dynamic tenant reconfiguration is already underway, with established retailers like GAP, Banana Republic, La Vie En Rose, Carter's OshKosh, Dormez-Vous, Dollarama, Sushi Shop, Thai Express, Service Canada, and SQDC relocating within the site to optimize layout and enhance the shopping experience. This reimagining also makes room for innovative new concepts, including Mondou's next-generation store and a refreshed Second Cup café, adding renewed energy and tenant mix to the centre.
Harden, in partnership with RioCan, continues to actively manage and enhance the remaining portions of Méga Centre Notre-Dame. A portion of these improvements is already complete, reflecting the partners' ongoing commitment to improve the site's layout, aesthetics, and visitor experience. This sustained effort underscores their dedication to shaping vibrant, welcoming spaces that support the community and long-term commercial vitality.
About Harden
Established in 1985, Harden is a second generation, family-owned real estate company whose primary focus is owning and operating commercial, residential, and industrial properties in many communities throughout the provinces of Quebec and Ontario. Vertically integrated, Harden specializes in all facets of the real estate development process, including, development, construction, leasing, and asset management.
To learn more about Harden, please visit
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNBC
41 minutes ago
- CNBC
CNBC's The China Connection newsletter: Wonders and woes of China's robotics industry
At the World Robot Conference in Beijing, which concluded Tuesday, the mood was a blend of optimism and caution: Businesses showed off increasingly lifelike humanoid robots even as they conceded that technological gaps keeping these machines from mainstream usage remain wide. Thousands turned up to watch humanoid robots to perform an array of unusual feats: from clumsily serving popcorn and drinks, spinning handkerchiefs, sparring in a boxing ring to playing chess and showcasing football skills. But none of these feats amounted to a technological breakthrough. While there have been improvements in design, maneuverability and appearance, the androids still struggle to process and respond to their surroundings, a limitation that keeps them from most real-life workplace roles. So far, their commercial use is mostly confined to guiding visitors at exhibition halls, shopping malls and, more recently, testing at factories for repetitive tasks like sorting materials and performing quality checks. "When will humanoid robots be able to do 80% of the physical work that human can do? That's decades away," said Jay Huang, managing director and head of Asia industrial technologies sector at Bernstein. "But what we will see is these individual tasks, like material handling, being multiplied into a much bigger scale. They can be used in very different format, different settings," Huang added. Some tasks like using a robot to make a bed are still in the "very early" stage, with low success rate, Huang said, "but that's the right direction to push the industry forward." Take PsiBot's mahjong-playing droid displayed at the event: It still misidentifies tiles, often confuses the game's rules and plays at a relatively slow pace, according to local media reports. The technological bottleneck for large-scale integration of humanoids into daily life stems from a lack of cutting-edge AI models and insufficient training data, said Bob Chen, economist at Shanghai-based FG Venture. The venture-capital firm has invested in robotics startups including Hangzhou-based DEEP Robotics that makes quadruped-robots — machines that mimic movements of four-legged creatures. Androids rely on vast troves of motion-capture, visual, tactile and audio data, along with simulations, to build the sensory and behavioral maps they need to navigate and interact in the real world. "Large language models have rather narrow function: language in, language out. But robots require far more complex, multimodal inputs, and their outputs are not words but actions and behaviors," said Chen, according to CNBC's translation of his comments in Mandarin. Several startups in China have invested in building "data factories," hiring people to operate robots or wearables to capture machine-interaction data to train bots. Humanoid robots are emerging as another front in China's tech rivalry with the U.S.— where they could prevail with cheaper prices and faster deployment. "China, the U.S. and other countries are playing on a quite leveled playing field," Huang said. "Just like in electric vehicles, autonomous driving, in humanoid robots, China acts extremely fast in product and use-case multiplication, while U.S. players seem to shoot for the holy-grail solution." In robot manufacturing, Tesla's humanoid project Optimus appears to be leading in the U.S., with CEO Elon Musk saying the company plans to produce about 5,000 units this year. While Musk's ambitious plans could give it a leg up on other American competitors that have yet to hit the mass market, Chinese companies have been racing to make their models more affordable. They are also believed to have been undercutting global peers in terms of price, thanks to superior cost controls. That's despite the real-world applications of robots remaining uncertain. In the lead up to the WRC, Unitree rolled out its third version of R1 model, priced at 39,900 yuan ($5,249) on e-commerce site significantly cheaper than the its other models. The company's H1 model was sold for 650,000 yuan per unit and G1 robot for 99,000 yuan. At the conference, prices for a humanoid robot ranged from tens of thousands of yuan to over 100,000 yuan, and the high-end models capable of more complex tasks were priced above 500,000 yuan. UniX AI touted its entry-level humanoid droids at just 88,000 yuan each. Shenzhen-based Engine AI has announced plans for a rival model starting at 38,500 yuan. Some U.S. companies such as Apptronik could see their attempt to rival Chinese humanoid robots be further undercut by U.S. tariffs as they still rely on some components from China. China already has an edge in integrating machinery into factory workflows and, in many cases, is outpacing rivals in marrying artificial intelligence with robotics, said Arthur Kroeber, founding partner of China-focused economic research firm Gavekal Dragonomics. Kroeber predicts that within two to four years, Chinese factories will achieve major efficiency gains across industries by combining top-tier industrial robots with AI systems that make them far more effective in varied settings. Some of UBTech Robotics' humanlike droids have been deployed at factories of carmakers BYD and Geely, at electronics manufacturer Foxconn and logistics giant SF Delivery, Chinese state media reported in April. However, during trainings, humanoid robots moved slowly, operating at just 20% of human efficiency, the report pointed out. "Enabling humanoid robots to map their moving routes, speed up movements and operate for long periods of time in uncomfortable temperature environments still requires vast amounts of data," it said. While widespread deployment of humanoid robots that enhance productivity might still be a distant prospect, Chinese companies are pushing ahead as their tech race with the U.S. heats up. Jeff Moon, founder and president of China Moon Strategies and former assistant U.S. trade representative for China, said the U.S. and China's overtures are well-choreographed and happening in a planned sequence, but they won't solve many of the underlying problems between the two countries. Graham Allison, Harvard professor and former assistant secretary of defense, said he expects a "grand rapprochement" or friendship between U.S. President Donald Trump and his Chinese counterpart Xi Jinping, especially as Trump needs a strong economy heading into the midterm elections. Hao Hong, managing partner and CIO of Lotus Asset Management, said traders and fund managers are not very concerned about weakening fundamentals in the Chinese markets as long as liquidity remains strong. U.S. and China secured a truce extension. The two countries agreed to delay by another 90 days the higher tariffs, imposed in April, on each other's goods. Beijing discouraging companies from using Nvidia chips. Chinese officials have asked companies to explain why they need to buy Nvidia chips instead of ones from domestic suppliers, according to a Reuters report. Trump says open to Nvidia selling downgraded version of advanced chip to China. Trump indicated that he will meet with Nvidia CEO Jensen Huang regarding the company's high-end Blackwell chip. Huang has said he hopes to sell more advanced chips to China. China and Hong Kong stocks rose as Asian markets tracked gains on Wall Street after the latest U.S. inflation data raised expectations that the Federal Reserve could cut interest rates next month. Mainland China's CSI 300 added 0.74%, while Hong Kong's Hang Seng Index — which includes major Chinese companies — had gained 2.2% as of 2:22 p.m. local time (2:22 a.m. ET). The mainland benchmark is up over 6% year to date, data from LSEG showed. The Hang Seng Tech index, which tracks the some of the largest mainland Chinese technology companies listed in Hong Kong, rose over 2%, lifted by Tencent Music Entertainment, which surged over 14%, a day after the company beat estimates for second-quarter revenue and profit. China's 10-year government bond yield currently stands at 1.723%.Aug 14: NetEase, June-quarter earnings Aug 14-17: World Humanoid Robot Games Aug 15: Urban investment, industrial output and retail sales, urban unemployment rate, house prices for July Aug 19: Xiaomi, Xpeng June-quarter earnings
Epoch Times
2 hours ago
- Epoch Times
The Hidden Math That Makes Some Australians Poorer for Working Harder
AD It may seem counterintuitive, but working longer hours can make you less money, the e61 Institute says. A pile of bills in Brisbane, Australia, on Oct. 30, 2013. AAP Image/Dan Peled 8/13/2025 | Updated: 8/13/2025 Not so long ago, working harder was thought to guarantee you were better off. Rex Widerstrom is a New Zealand-based reporter with over 40 years of experience in media, including radio and print. He is currently a presenter for Hutt Radio. Author's Selected Articles
Business Upturn
2 hours ago
- Business Upturn
Indoco Remedies gets USFDA nod for generic Rivaroxaban tablets; eyes growth in US Market
Mumbai-based Indoco Remedies Ltd. has secured final approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) to market Rivaroxaban Tablets USP in strengths of 2.5 mg, 10 mg, 15 mg, and 20 mg. The product is the generic equivalent of Janssen Pharmaceuticals' blockbuster anticoagulant, Xarelto, and will be manufactured at Indoco's Verna, Goa facility. The approved Rivaroxaban tablets are bioequivalent and therapeutically equivalent to Xarelto and are indicated for the treatment of venous thromboembolism (VTE). This approval marks another milestone in Indoco's push into the US generics market, one of the most lucrative pharmaceutical markets globally. Commenting on the development, Indoco Remedies' Managing Director Aditi Panandikar said, 'Besides reflecting the capability of Indoco Remedies to deliver products of high-quality standards, this development also provides impetus to our growth aspirations in an important market such as the US.' Indoco Remedies is a fully integrated, research-driven pharmaceutical company with a global footprint, generating over 106 million prescriptions annually in India alone. The company operates 11 manufacturing facilities — seven for finished dosage forms (FDFs) and four for active pharmaceutical ingredients (APIs) — all of which are approved by top global regulatory agencies including the USFDA and UK-MHRA. With a turnover of $180 million and a workforce of more than 6,000 employees, Indoco is known for popular domestic brands such as Cyclopam, Febrex Plus, Sensodent-K, Karvol Plus, ATM, Oxipod, and Cital. Internationally, the company partners with large generics players to expand its market reach across multiple geographies. The latest USFDA approval strengthens Indoco's product portfolio in the regulated market and could open up significant revenue opportunities as Rivaroxaban continues to be a widely prescribed oral anticoagulant in the US. Disclaimer: This news article is for informational purposes only and does not constitute investment advice. Investors should consult a qualified financial advisor before making investment decisions. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
